Carmed Pharmaceuticals, a science-driven company specializing in standardized carvacrol-based formulations, has announced its expansion into the United States market. The U.S. expansion is being formally announced in alignment with International Women’s Day, highlighting the company’s female leadership and its commitment to science-driven development within the preventive health sector. Founded on a structured research pathway rather than short-term wellness trends, Carmed integrates traditional botanical knowledge with modern pharmaceutical technology to develop quality-controlled formulations designed to support immune resilience, cellular health, and overall physiological balance.
Officially established in 2019 following several years of focused research and development, the company brings nearly 15 years of industry experience to its U.S. expansion strategy. "Our foundation is not built on trends," said Mustafa Can, founder of Carmed Pharmaceuticals. "From the beginning, our objective has been to develop scientifically structured formulations guided by mechanism-based research and rigorous quality control. We combine nature’s bioactive potential with disciplined pharmaceutical methodology." All Carmed products are manufactured in facilities operating in accordance with Good Manufacturing Practice principles and applicable regulatory standards, with an emphasis on safety, consistency, and long-term quality assurance.
Carmed Pharmaceuticals will introduce several of its flagship formulations to the U.S. market: Vacrol® Kids Spray– a carvacrol-based spray formulated to support upper respiratory wellness and microbial balance for children ages 4–11; S-Mix®– a synergy-driven formulation designed to support immune function and healthy cellular activity; and Omevaq-3®– a targeted formulation developed to support cellular energy metabolism and cognitive wellness. Vacrol® Kids Spray and S-Mix® are gluten-free, non-GMO, sugar-free, preservative-free, and halal-certified. "Our formulations are designed around rational synergy," Can added. "Rather than relying on single ingredients, we develop standardized combinations selected to interact across multiple biological pathways in a consistent and reproducible manner."
Carmed maintains academic collaborations and supports peer-reviewed research exploring bioactive mechanisms and formulation science. The company emphasizes that its research reflects scientific inquiry into botanical bioactivity and standardization practices and is not presented as evidence that its consumer products diagnose, treat, cure, or prevent any disease. As it enters the United States, Carmed states its strategy is focused on regulatory alignment, long-term credibility, and preventive wellness positioning. Distribution timelines and retail availability will be announced in the coming months. More information about the company's approach can be found on the Carmed Pharmaceuticals website.
